Correlation Between FrontView REIT, and Hikma Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both FrontView REIT, and Hikma Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining FrontView REIT, and Hikma Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between FrontView REIT, and Hikma Pharmaceuticals PLC, you can compare the effects of market volatilities on FrontView REIT, and Hikma Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in FrontView REIT, with a short position of Hikma Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of FrontView REIT, and Hikma Pharmaceuticals.
Diversification Opportunities for FrontView REIT, and Hikma Pharmaceuticals
0.34 | Correlation Coefficient |
Weak diversification
The 3 months correlation between FrontView and Hikma is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding FrontView REIT, and Hikma Pharmaceuticals PLC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hikma Pharmaceuticals PLC and FrontView REIT, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on FrontView REIT, are associated (or correlated) with Hikma Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hikma Pharmaceuticals PLC has no effect on the direction of FrontView REIT, i.e., FrontView REIT, and Hikma Pharmaceuticals go up and down completely randomly.
Pair Corralation between FrontView REIT, and Hikma Pharmaceuticals
Considering the 90-day investment horizon FrontView REIT, is expected to under-perform the Hikma Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, FrontView REIT, is 1.39 times less risky than Hikma Pharmaceuticals. The stock trades about -0.01 of its potential returns per unit of risk. The Hikma Pharmaceuticals PLC is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest 4,357 in Hikma Pharmaceuticals PLC on September 14, 2024 and sell it today you would earn a total of 675.00 from holding Hikma Pharmaceuticals PLC or generate 15.49% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 21.63% |
| Values | Daily Returns |
FrontView REIT, vs. Hikma Pharmaceuticals PLC
Performance |
| Timeline |
| FrontView REIT, |
| Hikma Pharmaceuticals PLC |
FrontView REIT, and Hikma Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with FrontView REIT, and Hikma Pharmaceuticals
The main advantage of trading using opposite FrontView REIT, and Hikma Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if FrontView REIT, position performs unexpectedly, Hikma Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hikma Pharmaceuticals will offset losses from the drop in Hikma Pharmaceuticals' long position.| FrontView REIT, vs. Hudson Pacific Properties | FrontView REIT, vs. Highway Holdings Limited | FrontView REIT, vs. JBG SMITH Properties | FrontView REIT, vs. RBC Bearings Incorporated |
| Hikma Pharmaceuticals vs. Viatris | Hikma Pharmaceuticals vs. Catalent | Hikma Pharmaceuticals vs. Bausch Health Companies | Hikma Pharmaceuticals vs. Tilray Inc |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Complementary Tools
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |